TASCENSO ODT

Peak

fingolimod lauryl sulfate

NDAORALTABLET, ORALLY DISINTEGRATING

Approved

Dec 2021

Lifecycle

Peak

Competitive Pressure

0/100

Data completeness

3/8 — Basic

Drug data last refreshed 4d ago · AI intelligence enriched 3w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

TASCENSO ODT is an orally disintegrating tablet formulation of fingolimod lauryl sulfate, a small-molecule sphingosine-1-phosphate receptor modulator. The specific indication(s) and mechanism of action are not detailed in available data, though fingolimod is clinically used in immunological conditions. This formulation innovation improves patient convenience through rapid oral dissolution.

$0.481MPart D

Peak9.7 years to LOE

Peak lifecycle status with modest Part D spending ($481K, 31 claims in 2023) suggests a niche formulation with limited commercial scale; brand team likely remains lean and focused on differentiation rather than volume expansion.

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Career Relevance

TASCENSO ODT shows zero linked job openings, indicating minimal active hiring or team expansion. Working on this product offers stability within a niche, mature brand but limited growth trajectory or role mobility within the organization.

External Resources

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.